{
    "guideline_identifier": "PIIS0923753422041928.txt",
    "cancer_focus": {
        "primary_cancer": "Metastatic Colorectal Cancer",
        "related_syndrome_or_condition": "Lynch Syndrome, BRAF V600E-mutant mCRC, HER2-amplified mCRC"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Resectable or potentially resectable metastases",
            "risk_group": "Favorable risk",
            "treatment_plans": [
                {
                    "clinical_context": "Resectable metastases with favorable risk",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Upfront surgery without perioperative chemotherapy",
                    "treatment_line": "Perioperative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Resectable or potentially resectable metastases",
            "risk_group": "Unfavorable risk",
            "treatment_plans": [
                {
                    "clinical_context": "Resectable metastases with unfavorable risk",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Perioperative FOLFOX (3 months pre- and post-surgery)",
                    "treatment_line": "Perioperative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Perioperative setting for resectable disease",
                    "recommendation_type": "Contraindication",
                    "recommendation_content": "Avoid anti-EGFR therapy",
                    "treatment_line": "Perioperative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I B"
                }
            ]
        },
        {
            "staging_criteria": "Resectable or potentially resectable metastases",
            "risk_group": "RAS-wt and left-sided",
            "treatment_plans": [
                {
                    "clinical_context": "Conversion therapy for initially unresectable disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOX/FOLFIRI + anti-EGFR (cetuximab/panitumumab)",
                    "treatment_line": "Conversion",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Wild-type",
                            "testing_guidance": "Mandatory at diagnosis (KRAS/NRAS exons 2/3/4)"
                        }
                    ],
                    "esmo_evidence_level": "Level II A"
                }
            ]
        },
        {
            "staging_criteria": "Resectable or potentially resectable metastases",
            "risk_group": "RAS-mut or right-sided",
            "treatment_plans": [
                {
                    "clinical_context": "Conversion therapy for initially unresectable disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOXIRI + bevacizumab or doublet chemotherapy + bevacizumab",
                    "treatment_line": "Conversion",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Mutant",
                            "testing_guidance": "Mandatory at diagnosis (KRAS/NRAS exons 2/3/4)"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                }
            ]
        },
        {
            "staging_criteria": "Oligometastatic disease",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "clinical_context": "Resectable oligometastatic lesions",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgery (gold standard)",
                    "treatment_line": "Local therapy",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II A"
                },
                {
                    "clinical_context": "Lesions ≤3 cm in non-surgical candidates",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Thermal ablation (RFA/MWA)",
                    "treatment_line": "Local therapy",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II B"
                },
                {
                    "clinical_context": "Inoperable oligometastatic lesions",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Stereotactic body radiotherapy (SBRT)",
                    "treatment_line": "Local therapy",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Peritoneal carcinomatosis",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "clinical_context": "Peritoneal metastases",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin",
                    "treatment_line": "Curative intent",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II B"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "RAS-wt and left-sided",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOX/FOLFIRI + anti-EGFR (cetuximab/panitumumab)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Wild-type",
                            "testing_guidance": "Mandatory at diagnosis (KRAS/NRAS exons 2/3/4)"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Maintenance after 4 months induction",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Fluoropyrimidine + anti-EGFR (if used initially)",
                    "treatment_line": "Maintenance",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Wild-type",
                            "testing_guidance": "Confirmatory testing recommended"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "RAS-mut or right-sided",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOX/CAPOX/FOLFIRI + bevacizumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Mutant",
                            "testing_guidance": "Mandatory at diagnosis (KRAS/NRAS exons 2/3/4)"
                        }
                    ],
                    "esmo_evidence_level": "Level I B"
                },
                {
                    "clinical_context": "Maintenance after 4 months induction",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Fluoropyrimidine + bevacizumab",
                    "treatment_line": "Maintenance",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I B"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "dMMR/MSI-H",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab or nivolumab (± ipilimumab)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "MMR/MSI",
                            "status": "Deficient/High",
                            "testing_guidance": "Mandatory at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "BRAF V600E-mut",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "FOLFOXIRI + bevacizumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF",
                            "status": "V600E mutant",
                            "testing_guidance": "Mandatory at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                },
                {
                    "clinical_context": "Second-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Encorafenib + cetuximab ± binimetinib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF",
                            "status": "V600E mutant",
                            "testing_guidance": "Confirmatory testing recommended"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "Frail patients",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Fluoropyrimidine monotherapy ± bevacizumab or anti-EGFR (for left-sided tumors)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Wild-type (if using anti-EGFR)",
                            "testing_guidance": "Mandatory for anti-EGFR eligibility"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "Prior anti-VEGF therapy",
            "treatment_plans": [
                {
                    "clinical_context": "Second-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Aflibercept/ramucirumab + FOLFIRI",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        },
        {
            "staging_criteria": "Unresectable advanced disease",
            "risk_group": "Refractory disease",
            "treatment_plans": [
                {
                    "clinical_context": "Third-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Regorafenib or trifluridine/tipiracil",
                    "treatment_line": "Third-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Anti-EGFR rechallenge",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Cetuximab/panitumumab retreatment (liquid biopsy-guided if prior response >6 months)",
                    "treatment_line": "Third-line+",
                    "biomarker_requirements": [
                        {
                            "name": "RAS",
                            "status": "Wild-type",
                            "testing_guidance": "Liquid biopsy monitoring required"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                },
                {
                    "clinical_context": "HER2-amplified tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Trastuzumab + lapatinib",
                    "treatment_line": "Third-line+",
                    "biomarker_requirements": [
                        {
                            "name": "HER2",
                            "status": "Amplified",
                            "testing_guidance": "IHC/FISH testing in RAS-wt tumors"
                        }
                    ],
                    "esmo_evidence_level": "Level III C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Biomarkers (RAS, BRAF, MSI/MMR, HER2, NTRK) determine eligibility for targeted therapies and immunotherapies, predict treatment efficacy, and have prognostic implications. For example: RAS wild-type predicts anti-EGFR response; MSI-H/dMMR indicates immunotherapy benefit; BRAF V600E mutation confers poor prognosis but responds to specific inhibitors."
    }
}